Señales en vivo de AVBP | Maximiza tus Ganancias con Getagraph.com

COMPRAR 123186 min ago

@ $21.16

Emitido: 14 feb 2024 @ 15:35

Retorno: -14.98%

Señal anterior: feb 13 - 13:28

Señal anterior: Vender

Retorno: -2.49 %

Live Chart Being Loaded With Signals

Commentary (9 may 2024 @ 16:00):

Stats
Volumen de hoy	29 725.00
Volumen promedio	178 925
Capitalización de mercado	602.55M
Próxima fecha de ganancias	( $0 ) 2024-06-27
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0810 (0.45%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-30	Hillhouse Investment Management, Ltd.	Buy	555 555	Common Stock
2024-01-30	Hillhouse Investment Management, Ltd.	Buy	313 076	Common Stock
2024-01-30	Hillhouse Investment Management, Ltd.	Buy	3 616 041	Common Stock
2024-01-30	Hillhouse Investment Management, Ltd.	Sell	4 761 903	Series B Preferred Stock
2024-01-30	Hillhouse Investment Management, Ltd.	Sell	55 000 000	Series A Preferred Stock

INSIDER POWER
-74.77
Last 24 transactions
Buy: 9 226 636 \| Sell: 63 909 387

Volumen Correlación

Largo: 0.31 (neutral)

Corto: 0.58 (weak)

Signal:(72.836) Neutral

ArriVent BioPharma, Inc. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ArriVent BioPharma, Inc. Correlación - Moneda/Commodity

-0.43
( neutral )

0.00
( neutral )

-0.25
( neutral )

-0.27
( neutral )

0.35
( neutral )

Financial Reports:

No articles found.

ArriVent BioPharma, Inc.

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.